GSK3B and myotonic dystrophy type 1: Our new data, together with the previously published studies, expand our knowledge about the benefits of the TG-GSK3β-CUGBP1 pathway in DM1 mouse models, suggesting that GSK3 inhibitors could be effective in DM1 patients of different ages, including pediatric, juvenile and adult patients with DM1.